Value of positron emission tomography (PET) for early response assessment during first-line or induction treatment.
| . | . | . | . | . | . | . | PFS@ 1 year . | |
|---|---|---|---|---|---|---|---|---|
| Author (ref) . | No. . | Histology . | Treatment . | Timing PET Cycles . | PPV for Relapse . | Mean Follow-Up (months) . | PET + . | PFS@ 1 year PET − . |
| Abbreviations: PPV: positive predictive value; PFS: progression free survival; PET+, residual disease on PET; PET−, complete metabolic response; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease | ||||||||
| Jerusalem (23) | 28 | NHL | first-line relapse | 2–5 | 100% | 28 | 20% | 81% |
| Mikhaeel (24) | 23 | NHL | first-line | 2–4 | 87% | 30 | 12% | 100% |
| Mikhaeel (25) | 32 | HD | first-line | 2–4 | 100% | 36 | 0% | 92% |
| Kostakoglu (26) | 30 | NHL/HD | first-line relapse | 1 | 87% | 19 | 13% | 87% |
| Spaepen (27) | 70 | NHL | first-line | 3–4 | 100% | 36 | 10% | 92% |
| Zijlstra (28) | 26 | NHL | first-line | 2 | 75% | 25 | 42% | 80% |
| . | . | . | . | . | . | . | PFS@ 1 year . | |
|---|---|---|---|---|---|---|---|---|
| Author (ref) . | No. . | Histology . | Treatment . | Timing PET Cycles . | PPV for Relapse . | Mean Follow-Up (months) . | PET + . | PFS@ 1 year PET − . |
| Abbreviations: PPV: positive predictive value; PFS: progression free survival; PET+, residual disease on PET; PET−, complete metabolic response; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease | ||||||||
| Jerusalem (23) | 28 | NHL | first-line relapse | 2–5 | 100% | 28 | 20% | 81% |
| Mikhaeel (24) | 23 | NHL | first-line | 2–4 | 87% | 30 | 12% | 100% |
| Mikhaeel (25) | 32 | HD | first-line | 2–4 | 100% | 36 | 0% | 92% |
| Kostakoglu (26) | 30 | NHL/HD | first-line relapse | 1 | 87% | 19 | 13% | 87% |
| Spaepen (27) | 70 | NHL | first-line | 3–4 | 100% | 36 | 10% | 92% |
| Zijlstra (28) | 26 | NHL | first-line | 2 | 75% | 25 | 42% | 80% |